Tuberculosis and Atypical Mycobacterial Infections

Tropical Infectious Diseases

Volumn , Issue , 2011, Pages 228-247

  Jones Lopez, Edward C ^a   Ellner, Jerrold J ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885156621     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7020-3935-5.00035-5     Document Type: Chapter

References (377)

1. Kaur D, Guerin ME, Skovierová H, et al. Biogenesis of the cell wall and other glycoconjugates of Mycobacterium tuberculosis. Adv Appl Microbiol 2009, 69:23.
2. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998, 393:537.
3. Filliol I, Motiwala AS, Cavatore M, et al. Global phylogeny of Mycobacterium tuberculosis based on single nucleotide polymorphism (SNP) analysis: insights into tuberculosis evolution, phylogenetic accuracy of other DNA fingerprinting systems, and recommendations for a minimal standard SNP set. J Bacteriol 2006, 188(2):759.
4. Grzybowski S, Barnett GD, Styblo K Contacts of cases of active pulmonary tuberculosis. Bull Int Union Tuberc 1975, 50:90.
5. Morrison J, Pai M, Hopewell PC Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect 0Dis 2008, 8(6):359.
6. Yeager H, Lacy J, Smith LR, et al. Quantitative studies of mycobacterial populations in sputum and saliva. Am Rev Respir Dis 1967, 95:998.
7. Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999, 353:444.
8. McLaughlin SI, Spradling P, Drociuk D, et al. Extensive transmission of Mycobacterium tuberculosis among congregated, HIV-infected prison inmates in South Carolina, United States. Int J Tuberc Lung Dis 2003, 7(7):665.
9. WHO Global TB Control - Surveillance, Planning, Financing. WHO/HTM/TB 2009, World Health Organization, Geneva.
10. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003, 163:1009.
11. Frieden TR, Sterling TR, Munsiff SS, et al. Tuberculosis. Lancet 2003, 362:887.
12. Murray CJ, Styblo K, Rouillon A Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc Lung Dis 1990, 65:6.
13. Kochi A The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 1991, 72:1.
14. De Cock KM, Chaisson RE Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis 1999, 3:457.
15. Comstock GW, Livesay VT, Woolpert SF The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974, 99:131.
16. O'Brien RJ, Perriens JH Preventive therapy for tuberculosis in HIV infection: the promise and the reality. AIDS 1995, 9:665.
17. Sonnenberg P, Glynn JR, Fielding K, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005, 191(2):150.
18. Geldmacher C, Schuetz A, Ngwenyama N, et al. Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis 2008, 198(11):1590.
19. Brenchley JM, Douek DC HIV infection and the gastrointestinal immune system. Mucosal Immunol 2008, 1(1):23.
20. Corbett EL, Charalambous S, Fielding K, et al. Stable incidence rates of tuberculosis (TB) among human immunodeficiency virus (HIV)-negative South African gold miners during a decade of epidemic HIV-associated TB. J Infect Dis 2003, 188(8):1156.
21. Corbett EL, Marston B, Churchyard BG, De Cock K Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006, 367(9514):926.
22. Mugusi F, Villamor E, Urassa W, et al. HIV co-infection, CD4 cell counts and clinical correlates of bacillary density in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006, 10(6):663.
23. Cruciani M, Malena M, Bosco O, et al. The impact of human immunodeficiency virus type 1 on infectiousness of tuberculosis: a meta-analysis. Clin Infect Dis 2001, 33(11):1922.
24. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992, 326:231.
25. Di Perri G, Cruciani M, Danzi MC, et al. Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet 1989, 2:1502.
26. Sonnenberg P, Murray J, Glynn JR, et al. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001, 358:1687.
27. Churchyard GJ, Fielding K, Charalambous S, et al. Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy?. AIDS 2003, 17(14):2063.
28. Chaisson RE, Schecter GF, Theuer CP, et al. Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival. Am Rev Respir Dis 1987, 136:570.
29. Small PM, Schecter GF, Goodman PC, et al. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991, 324:289.
30. Jones BE, Otaya M, Antoniskis D, et al. A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection. Am J Respir Crit Care Med 1994, 150:1499.
31. Perriens JH, St.Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995, 332:779.
32. Ackah AN, Coulibaly D, Digbeu H, et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan. Cote d'Ivoire. Lancet 1995, 345:607.
33. Whalen C, Horsburgh CR, Hom D, et al. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995, 151:129.
34. Toossi Z Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. J Infect Dis 2003, 188(8):1146.
35. Wallis RS, Vjecha M, Amir-Tahmasseb M, et al. Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated beta 2-microglobulin in HIV-1-associated tuberculosis. J Infect Dis 1993, 167:43.
36. Ansari NA, Kombe AH, Kenyon TA, et al. Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998. Int J Tuberc Lung Dis 2002, 6:55.
37. Lucas SB, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a west African city. AIDS 1993, 7:1569.
38. World Health Organization Anti-Tuberculosis Drug Resistance in the World: The WHO/IUTLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance 2001, World Health Organization, Geneva, Switzerland.
39. Badri M, Wilson D, Wood R, et al. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002, 359(9323):2059.
40. Santoro-Lopes G, de Pinho AM, Harrison LH, Schechter M Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002, 34(4):543.
41. Cobelens FG, Egwaga SM, van Ginkel T, et al. Tuberculin skin testing in patients with HIV infection: limited benefit of reduced cutoff values. Clin Infect Dis 2006, 43(5):634.
42. Karalliedde S, Katugaha LP, Uragoda CG Tuberculin response of Sri Lankan children after BCG vaccination at birth. Tubercle 1987, 68:33.
43. Farhat M, Greenaway C, Pai M, Menzies D False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?. Int J Tuberc Lung Dis 2006, 10(11):1192.
44. Pai M, Zwerling A, Menzies D Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008, 149(3):177.
45. Pai M, Kalantri S, Menzies D Discordance between tuberculin skin test and interferon-gamma assays. Int J Tuberc Lung Dis 2006, 10(8):942.
46. Dewan PK, Grinsdale J, Liska S, et al. Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay. BMC Infect Dis 2006, 6:47.
47. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989, 320:545.
48. Anonymous. Tuberculosis and AIDS - Connecticut. MMWR Morb Mortal Wkly Rep 1987, 36:133.
49. Proudfoot AT, Akhtar AJ, Douglas AC, et al. Miliary tuberculosis in adults. BMJ 1969, 2:273.
50. Stead WW, Kerby GR, Schlueter DP, et al. The clinical spectrum of primary tuberculosis in adults. Confusion with reinfection in the pathogenesis of chronic tuberculosis. Ann Intern Med 1968, 68:731.
51. Guwatudde D, Nakakeeto M, Jones-Lopez EC, et al. Tuberculosis in household contacts of infectious cases in Kampala, Uganda. Am J Epidemiol 2003, 158(9):887.
52. Khan MA, Kovnat DM, Bachus B, et al. Clinical and roentgenographic spectrum of pulmonary tuberculosis in the adult. Am J Med 1977, 62:31.
53. Palmer PE Pulmonary tuberculosis - usual and unusual radiographic presentations. Semin Roentgenol 1979, 14:204.
54. Segarra R, Sherman DJ, Rodriguez-Aguero J Lower lung field tuberculosis. Am Rev Respir Dis 1963, 87:37.
55. Barza M, Weinstein L Uncommon presentations of pulmonary tuberculosis in adults. Postgrad Med 1972, 51:143.
56. Davis SD, Yankelevitz DF, Williams T, et al. Pulmonary tuberculosis in immunocompromised hosts: epidemiological, clinical, and radiological assessment. Semin Roentgenol 1993, 28:119.
57. Goodman PC Pulmonary tuberculosis in patients with acquired immunodeficiency syndrome. J Thorac Imaging 1990, 5:38.
58. McAdams HP, Erasmus J, Winter JA Radiologic manifestations of pulmonary tuberculosis. Radiol Clin North Am 1995, 33:655.
59. Schaaf HS, Beyers N, Gie RP, et al. Respiratory tuberculosis in childhood: the diagnostic value of clinical features and special investigations. Pediatr Infect Dis J 1995, 14:189.
60. Houwert KA, Borggreven PA, Schaaf HS, et al. Prospective evaluation of World Health Organization criteria to assist diagnosis of tuberculosis in children. Eur Respir J 1998, 11:1116.
61. Donald PR, Fourie PB, Grange JM Tuberculosis in Childhood 1999, J.L. Van Shaik, Pretoria, South Africa.
62. Greenberg SD, Frager D, Suster B, et al. Active pulmonary tuberculosis in patients with AIDS. Spectrum of radiographic findings (including a normal appearance). Radiology 1994, 193:115.
63. Keiper MD, Beumont M, Elshami A, et al. CD4 T lymphocyte count and the radiographic presentation of pulmonary tuberculosis. A study of the relationship between these factors in patients with human immunodeficiency virus infection. Chest 1995, 107:74.
64. Lucas SB, Peacock CS, Hounnou A, et al. Disease in children infected with HIV in Abidjan, Cote d'Ivoire. BMJ 1996, 312:335.
65. Pitchenik AE, Burr J, Suarez M, et al. Human T-cell lymphotropic virus-III (HTLV-III) seropositivity and related disease among 71 consecutive patients in whom tuberculosis was diagnosed. A prospective study. Am Rev Respir Dis 1987, 135:875.
66. Pitchenik AE, Cole C, Russell BW, et al. Tuberculosis, atypical mycobacteriosis, and the acquired immunodeficiency syndrome among Haitian and non-Haitian patients in south Florida. Ann Intern Med 1984, 101:641.
67. Handwerger S, Mildvan D, Senie R, et al. Tuberculosis and the acquired immunodeficiency syndrome at a New York City hospital: 1978-1985. Chest 1987, 91:176.
68. Louie E, Rice LB, Holzman RS Tuberculosis in non-Haitian patients with acquired immunodeficiency syndrome. Chest 1986, 90:542.
69. Reider HL, Cauthen GM, Comstock GW, et al. Epidemiology of tuberculosis in the United States. Epidemiol Rev 1989, 11:29.
70. Rieder HL, Cauthen GM, Bloch AB, et al. Tuberculosis and acquired immunodeficiency syndrome - Florida. Arch Intern Med 1989, 149:1268.
71. Tuberculosis and acquired immunodeficiency syndrome - New York City. MMWR Morb Mortal Wkly Rep 1987, 36:785.
72. Perlman DC, el-Sadr WM, Nelson ET, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. Clin Infect Dis 1997, 25:242.
73. Shafer RW, Goldberg R, Sierra M, et al. Frequency of Mycobacterium tuberculosis bacteremia in patients with tuberculosis in an area endemic for AIDS. Am Rev Respir Dis 1989, 140:1611.
74. Kramer F, Modilevsky T, Waliany AR, et al. Delayed diagnosis of tuberculosis in patients with human immunodeficiency virus infection. Am J Med 1990, 89:451.
75. Modilevsky T, Sattler FR, Barnes PF Mycobacterial disease in patients with human immunodeficiency virus infection. Arch Intern Med 1989, 149:2201.
76. Long R, Maycher B, Scalcini M, et al. The chest roentgenogram in pulmonary TB patients seropositive for human immunodeficiency virus type 1. Chest 1991, 99:123.
77. Brindle RJ, Nunn PP, Githui W, et al. Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis. Am Rev Respir Dis 1993, 147:958.
78. Elliott AM, Namaambo K, Allen BW, et al. Negative sputum smear results in HIV-positive patients with pulmonary tuberculosis in Lusaka, Zambia. Tuberc Lung Dis 1993, 74:191.
79. Klein NC, Duncanson FP, Lenox TH, et al. Use of mycobacterial smears in the diagnosis of pulmonary tuberculosis in AIDS/ARC patients. Chest 1989, 95:1190.
80. Perronne C, Ghoubontni A, Leport C, et al. Should pulmonary tuberculosis be an AIDS-defining diagnosis in patients infected with HIV?. Tuberc Lung Dis 1992, 73:39.
81. Theuer CP, Hopewell PC, Elias D, et al. Human immunodeficiency virus infection in tuberculosis patients. J Infect Dis 1990, 162:8.
82. Di Perri G, Cazzadori A, Vento S, et al. Comparative histopathological study of pulmonary tuberculosis in human immunodeficiency virus-infected and non-infected patients. Tuberc Lung Dis 1996, 77:244.
83. Cauthen GM, Dooley SW, Onorato IM, et al. Transmission of Mycobacterium tuberculosis from tuberculosis patients with HIV infection or AIDS. Am J Epidemiol 1996, 144:69.
84. Cruciani M, Malena M, Bosco O, et al. The impact of human immunodeficiency virus type 1 on infectiousness of tuberculosis: a meta-analysis. Clin Infect Dis 2001, 33:1922.
85. Carvalho AC, DeRiemer K, Nunes ZB, et al. Transmission of Mycobacterium tuberculosis to contacts of HIV-infected tuberculosis patients. Am J Respir Crit Care Med 2001, 164:2166.
86. Klausner JD, Ryder RW, Baende E, et al. Mycobacterium tuberculosis in household contacts of human immunodeficiency virus type1-seropositive patients with active pulmonary tuberculosis in Kinshasa, Zaire. J Infect Dis 1993, 168:106.
87. Nunn P, Mungai M, Nyamwaya J, et al. The effect of human immunodeficiency virus type-1 on the infectiousness of tuberculosis. Tuberc Lung Dis 1994, 75:25.
88. Espinal MA, Perez EN, Baez J, et al. Infectiousness of Mycobacterium tuberculosis in HIV-1-infected patients with tuberculosis: a prospective study. Lancet 2000, 355:275.
89. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345(15):1098.
90. Wallis RS Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008, 8(10):601.
91. Liao CH, Chou CH, Lai CC, et al. Diagnostic performance of an enzyme-linked immunospot assay for interferon-gamma in extrapulmonary tuberculosis varies between different sites of disease. J Infect 2009, 59(6):402.
92. Wallgren A The time-table of tuberculosis. Tubercle 1948, 29:245.
93. Saks AM, Posner R Tuberculosis in HIV positive patients in South Africa: a comparative radiological study with HIV negative patients. Clin Radiol 1992, 46:387.
94. Frye MD, Pozsik CJ, Sahn SA Tuberculous pleurisy is more common in AIDS than in non-AIDS patients with tuberculosis. Chest 1997, 112:393.
95. Allen JC, Apicella MA Experimental pleural effusion as a manifestation of delayed hypersensitivity to tuberculin PPD. J Immunol 1968, 101:481.
96. Fujiwara H, Tsuyuguchi I Frequency of tuberculin-reactive T-lymphocytes in pleural fluid and blood from patients with tuberculous pleurisy. Chest 1986, 89:530.
97. Shimokata K, Kawachi H, Kishimoto H, et al. Local cellular immunity in tuberculous pleurisy. Am Rev Respir Dis 1982, 126:822.
98. Ribera E, Ocana I, Martinez-Vazquez JM, et al. High level of interferon gamma in tuberculous pleural effusion. Chest 1988, 93:308.
99. Ribera E, Espanol T, Martinez-Vazquez JM, et al. Lymphocyte proliferation and gamma-interferon production after "in vitro" stimulation with PPD. Differences between tuberculous and nontuberculous pleurisy in patients with positive tuberculin skin test. Chest 1990, 97:1381.
100. Barnes PF, Fong SJ, Brennan PJ, et al. Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis. J Immunol 1990, 145:149.
101. Hodsdon WS, Luzze H, Hurst TJ, et al. HIV-1-related pleural tuberculosis: Elevated production of IFN-gamma, but failure of immunity to Mycobacterium tuberculosis. AIDS 2001, 15:467.
102. Levine H, Szanto PB, Cugell DW Tuberculous pleurisy. An acute illness. Arch Intern Med 1968, 122:329.
103. Berger HW, Mejia E Tuberculous pleurisy. Chest 1973, 63:88.
104. Sibley JC A study of 200 cases of tuberculous pleurisy with effusion. Am Rev Tuberc 1950, 62:314.
105. Ellner JJ Pleural fluid and peripheral blood lymphocyte function in tuberculosis. Ann Intern Med 1978, 89:932.
106. Ellner JJ Suppressor adherent cells in human tuberculosis. J Immunol 1978, 121:2573.
107. Hurwitz S, Leiman G, Shapiro C Mesothelial cells in pleural fluid: TB or not TB?. S Afr Med J 1980, 57:937.
108. Valdes L, Pose A, San Jose E, et al. Tuberculous pleural effusions. Eur J Intern Med 2003, 14:77.
109. Scharer L, McClement JH Isolation of tubercle bacilli from needle biopsy specimens of parietal pleura. Am Rev Respir Dis 1968, 97:466.
110. Levine H, Metzger W, Lacera D, et al. Diagnosis of tuberculous pleurisy by culture of pleural biopsy specimen. Arch Intern Med 1970, 126:269.
111. Luzze H, Elliott AM, Joloba ML, et al. Evaluation of suspected tuberculous pleurisy: clinical and diagnostic findings in HIV-1-positive and HIV-negative adults in Uganda. Int J Tuberc Lung Dis 2001, 5:746.
112. Patiala J Initial tuberculous pleuritis in the Finnish armed forces in 1939-1945 with special reference to eventual post-pleuritic tuberculosis. Acta Tuberc Scand Suppl 1954, 15:1.
113. Roper WH, Waring JJ Primary serofibrinous pleurisy with effusion in military personnel. Am Rev Tuberc 1955, 71:616.
114. Dutt AK, Moers D, Stead WW Short-course chemotherapy for pleural tuberculosis. Nine years' experience in routine treatment service. Chest 1986, 90:112.
115. Dutt AK, Moers D, Stead WW Tuberculous pleural effusion: 6-month therapy with isoniazid and rifampin. Am Rev Respir Dis 1992, 145:1429.
116. Lee CH, Wang WJ, Lan RS, et al. Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study. Chest 1988, 94:1256.
117. Sahn SA, Iseman MD Tuberculous empyema. Semin Respir Infect 1999, 14:82.
118. Glasser RM, Walker RI, Herion JC The significance of hematologic abnormalities in patients with tuberculosis. Arch Intern Med 1970, 125:691.
119. Sahn SA, Neff TA Miliary tuberculosis. Am J Med 1974, 56:494.
120. Maartens G, Willcox PA, Benatar SR Miliary tuberculosis: Rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults. Am J Med 1990, 89:291.
121. Munt PW Miliary tuberculosis in the chemotherapy era: with a clinical review in 69 American adults. Medicine (Baltimore) 1972, 51:139.
122. Gelb AF, Leffler C, Brewin A, et al. Miliary tuberculosis. Am Rev Respir Dis 1973, 108:1327.
123. Berger HW, Samortin TG Miliary tuberculosis: diagnostic methods with emphasis on the chest roentgenogram. Chest 1970, 58:586.
124. Grieco MH, Chmel H Acute disseminated tuberculosis as a diagnostic problem. A clinical study based on twenty-eight cases. Am Rev Respir Dis 1974, 109:554. 156.
125. Bobrowitz ID Active tuberculosis undiagnosed until autopsy. Am J Med 1982, 72:650.
126. Kim JH, Langston AA, Gallis HA Miliary tuberculosis: epidemiology, clinical manifestations, diagnosis, and outcome. Rev Infect Dis 1990, 12:583.
127. Burk JR, Viroslav J, Bynum LJ Miliary tuberculosis diagnosed by fibreoptic bronchoscopy and transbronchial biopsy. Tubercle 1978, 59:107.
128. Ramachandran P, Duraipandian M, Nagarajan M, et al. Three chemotherapy studies of tuberculous meningitis in children. Tubercle 1986, 67:17.
129. Berenguer J, Moreno S, Laguna F, et al. Tuberculous meningitis in patients infected with the human immunodeficiency virus. N Engl J Med 1992, 326:668.
130. Shafer RW, Kim DS, Weiss JP, et al. Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection. Medicine (Baltimore) 1991, 70:384.
131. Bouza E, Martin-Scapa C, Bernaldo de Quiros JC, et al. High prevalence of tuberculosis in AIDS patients in Spain. Eur J Clin Microbiol Infect Dis 1988, 7:785.
132. Auerbach O Tuberculous meningitis: correlation of therapeutic results with the pathogenesis and pathologic changes. I. General considerations and pathogenesis. Am Rev Tuberc 1951, 64:408.
133. Rich AR, McCordock HA The pathogenesis of tuberculous meningitis. Johns Hopkins Hosp Bull 1933, 52:5.
134. Idriss ZH, Sinno AA, Kronfol NM Tuberculous meningitis in childhood. Forty-three cases. Am J Dis Child 1976, 130:364.
135. Barrett-Connor E Tuberculous meningitis in adults. South Med J 1967, 60:1061.
136. Klein NC, Damsker B, Hirschman SZ Mycobacterial meningitis. Retrospective analysis from 1970 to 1983. Am J Med 1985, 79:29.
137. Kennedy DH, Fallon RJ Tuberculous meningitis. JAMA 1979, 241:264.
138. Dube MP, Holtom PD, Larsen RA Tuberculous meningitis in patients with and without human immunodeficiency virus infection. Am J Med 1992, 93:520.
139. Thwaites GE, Duc Bang N, Huy Dung N, et al. The influence of HIV infection on clinical presentation, response to treatment and outcome of adults with tuberculous meningitis. J Infect Dis 2005, 192:2134.
140. Crocco JA, Blecker MJ, Rooney JJ, et al. Tuberculous meningitis in adults: Clinical analysis. NY State J Med 1980, 80:1231.
141. Stockstill MT, Kauffman CA Comparison of cryptococcal and tuberculous meningitis. Arch Neurol 1983, 40:81.
142. Zarabi M, Sane S, Girdany BR The chest roentgenogram in the early diagnosis of tuberculous meningitis in children. Am J Dis Child 1971, 121:389.
143. Hinman AR Tuberculous meningitis at Cleveland Metropolitan General Hospital 1959 to 1963. Am Rev Respir Dis 1967, 95:670.
144. Sumaya CV, Simek M, Smith MH, et al. Tuberculous meningitis in children during the isoniazid era. J Pediatr 1975, 87:43.
145. Haas EJ, Madhavan T, Quinn EL, et al. Tuberculous meningitis in an urban general hospital. Arch Intern Med 1977, 137:1518.
146. Karandanis D, Shulman JA Recent survey of infectious meningitis in adults: review of laboratory findings in bacterial, tuberculous, and aseptic meningitis. South Med J 1976, 69:449.
147. Smith J, Godwin-Austen R Hypersecretion of anti-diuretic hormone due to tuberculous meningitis. Postgrad Med J 1980, 56:41.
148. Lincoln EM, Sordillo SVR, Davies PA Tuberculous meningitis in children. A review of 167 untreated and 74 treated patients with special reference to early diagnosis. J Pediatr 1960, 57:807.
149. Fishman RA The Cerebrospinal Fluid in Diseases of the Nervous System 1980, WB Saunders, Philadelphia.
150. Lepper MH, Spies HW The present status of the treatment of tuberculosis of the central nervous system. Ann NY Acad Sci 1963, 106:106.
151. Ogawa SK, Smith MA, Brennessel DJ, et al. Tuberculous meningitis in an urban medical center. Medicine (Baltimore) 1987, 66:317.
152. Miorner H, Sjobring U, Nayak P, et al. Diagnosis of tuberculous meningitis: a comparative analysis of 3 immunoassays, an immune complex assay and the polymerase chain reaction. Tuberc Lung Dis 1995, 76:381.
153. Kaur A, Basha A, Ranjan M, et al. Poor diagnostic value of adenosine deaminase in pleural, peritoneal and cerebrospinal fluids in tuberculosis. Indian J Med Res 1992, 95:270.
154. Seth P, Ahuja GK, Bhanu NV, et al. Evaluation of polymerase chain reaction for rapid diagnosis of clinically suspected tuberculous meningitis. Tuberc Lung Dis 1996, 77:353.
155. Ellner JJ, Bennett JE Chronic meningitis. Medicine (Baltimore) 1976, 55:341.
156. Torok ME, Trung Nghia HD, Hoang Mai NT, et al. Validation of a diagnostic algorithm for adult tuberculous meningitis. Am Soc Trop Med Hyg 2007, 77:555.
157. DesPrez RM, Boone IU Metabolism of O14-isoniazid in humans. Am Rev Respir Dis 1961, 84:42.
158. Tuchman AJ, Berger S, Daras M Cerebrospinal fluid penetration of anti-infective agents. South Med J 1984, 77:1443.
159. Donald PR, Schoeman JF, Van Zyl LE, et al. Intensive short course chemotherapy in the management of tuberculous meningitis. Int J Tuberc Lung Dis 1998, 2:704.
160. Thwaites GE, Duc Bang N, Huy Dung N, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004, 351:1741.
161. Thwaites GE, Macmullen-Price J, Hong Chau TH, et al. Serial MRI to determine the effect of dexamethasone on the cerebral pathology of tuberculous meningitis; an observational study. Lancet Neurol 2007, 6:230.
162. Kilpatrick ME, Girgis NI, Yassin MW, et al. Tuberculous meningitis - clinical and laboratory review of 100 patients. J Hyg (London) 1986, 96:231.
163. Smith AL Tuberculous meningitis in childhood. Med J Aust 1975, 1:57.
164. Lawn SD, Wilkinson RJ, Lipman MCI, et al. Immune reconstitution and "unmasking" tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008, 177:680.
165. Baalwa J, Mayanja-Kizza H, Kamya MR, et al. Worsening and unmasking of tuberculosis in HIV-1 infected patients after initiating highly-active antiretroviral therapy in Uganda. Afr Health Sci 2008, 8:190.
166. Castelnuovo B, Manabe YC, Kiragga A, et al. Cause specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in and urban African cohort. Clin Infect Dis 2009, 49:965.
167. Pepper DJ, Marais S, Maartens G, et al. Neurologic manifestations of tuberculosis associated immune reconstitution syndrome. Clin Infect Dis 2009, 48:e96.
168. Rivas-Santiago B, Schwander SK, Sarabia C, et al. Human β-defensin 2 is expressed and associated with Mycobacterium tuberculosis during infection of human alveolar epithelial cells. Infect Immun 2005, 73(8):4505.
169. + T cell differentiation during viral infection. Immunity 2007, 27(3):393.
170. + T cells. Infect Immun 1987, 55:2037.
171. Orme IM Characteristics and specificity of acquired immunologic memory to Mycobacterium tuberculosis infection. J Immunol 1988, 140:3589.
172. Jones BE, Young SM, Antoniskis D, et al. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993, 148:1292.
173. Barnes PF, Bloch AB, Davidson PT, et al. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991, 324:1644.
174. + T cells in human tuberculosis. Proc Natl Acad Sci USA 2000, 97:12210.
175. + T cells preferentially recognize heavily infected cells. Am J Respir Crit Care Med 2003, 168:1346.
176. Teitelbaum R, Glatman-Freedman A, Chen B, et al. A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci USA 1998, 95:15688.
177. Glatman-Freedman A Advances in antibody-mediated immunity against Mycobacterium tuberculosis: implications for a novel vaccine strategy. FEMS Immunol Med Microbiol 2003, 39:9.
178. van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999, 341:1174.
179. Nardell E, McInnis B, Thomas B, et al. Exogenous reinfection with tuberculosis in a shelter for the homeless. N Engl J Med 1986, 315:1570.
180. Alland D, Kalkut GE, Moss AR, et al. Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994, 330:1710.
181. Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med 1994, 330:1703.
182. Hirsch CS, Toossi Z, Othieno C, et al. Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy. J Infect Dis 1999, 180:2069.
183. Manca C, Tsenova L, Barry CE, et al. Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. J Immunol 1999, 162:6740.
184. Canetti G Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis 1965, 92:687.
185. Temple B, Ayakaka I, Ogwang S, et al. Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. Clin Infect Dis 2008, 47(9):1126.
186. Mitchison DA, Nunn AJ Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986, 133:423.
187. Shah N, Wright A, Drobniewski F Extreme drug resistance in tuberculosis ("XDR-TB"): global survey of supranational reference laboratories for Mycobacterium tuberculosis with resistance to second line drugs. Int J Tuberc Lung Dis 2005, 9(suppl 1):S77.
188. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368(9547):1575.
189. Koenig R Drug-resistant tuberculosis. In South Africa, XDR TB and HIV prove a deadly combination. Science 2008, 319(5865):894.
190. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008, 359(6):563.
191. Espinal MA, Laserson K, Camacho M, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001, 5:887.
192. Temple B, Ayakaka I, Ogwang S, et al. Rate and amplification of drug resistance in previously-treated tuberculosis patients in Kampala, Uganda. Clin Infect Dis 2008, 47(9):1126.
193. Hobby GL, Holman AP, Iseman MD, et al. Enumeration of tubercle bacilli in sputum of patients with pulmonary tuberculosis. Antimicrob Agents Chemother 1973, 4:94.
194. Dutt AK, Stead WW Short-course chemotherapy. The Arkansas experience. Chest 1981, 80:724.
195. Gunnels JJ, Bates JH, Swindoll H Infectivity of sputum-positive tuberculous patients on chemotherapy. Am Rev Respir Dis 1974, 109:323.
196. Kim TC, Blackman RS, Heatwole KM, et al. Acid-fast bacilli in sputum smears of patients with pulmonary tuberculosis. Prevalence and significance of negative smears pretreatment and positive smears post-treatment. Am Rev Respir Dis 1984, 129:264.
197. Narain R, Rao MS, Chandrasekhar P, et al. Microscopy positive and microscopy negative cases of pulmonary tuberculosis. Am Rev Respir Dis 1971, 103:761.
198. Kubica GP, Gross WM, Hawkins JE, et al. Laboratory services for mycobacterial diseases. Am Rev Respir Dis 1975, 112:773.
199. Berean K, Roberts FJ The reliability of acid fast stained smears of gastric aspirate specimens. Tubercle 1988, 69:205.
200. Klotz SA, Penn RL Acid-fast staining of urine and gastric contents is an excellent indicator of mycobacterial disease. Am Rev Respir Dis 1987, 136:1197.
201. Danek SJ, Bower JS Diagnosis of pulmonary tuberculosis by flexible fiberoptic bronchoscopy. Am Rev Respir Dis 1979, 119:677.
202. So SY, Lam WK, Yu DY Rapid diagnosis of suspected pulmonary tuberculosis by fiberoptic bronchoscopy. Tubercle 1982, 63:195.
203. Wallace JM, Deutsch AL, Harrell JH, et al. Bronchoscopy and transbronchial biopsy in evaluation of patients with suspected active tuberculosis. Am J Med 1981, 70:1189.
204. Kennedy DJ, Lewis WP, Barnes PF Yield of bronchoscopy for the diagnosis of tuberculosis in patients with human immunodeficiency virus infection. Chest 1992, 102:1040.
205. Willcox PA, Benatar SR, Potgieter PD Use of the flexible fibreoptic bronchoscope in diagnosis of sputum-negative pulmonary tuberculosis. Thorax 1982, 37:598.
206. Watterson SA, Drobniewski FA Modern laboratory diagnosis of mycobacterial infections. J Clin Pathol 2000, 53:727.
207. Dunlap NE, Bass J, Fujiwara P, et al. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000, 161:1376.
208. Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep 2009, 58(1):7.
209. Kent PT, Kubica GP Public Health Mycobacteriology: A Guide for the Level III Laboratory 1985, Centers for Disease Control, Atlanta.
210. Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull WHO 1969, 41:21.
211. Medical Research Council Streptomycin treatment of pulmonary tuberculosis. BMJ 1948, 2:769.
212. Pitts FW Tuberculosis: prevention and therapy. Current Concepts of Infectious Diseases 1977, 181. John Wiley, New York. E.W. Hook, G.L. Mandell, J.M. Gwaltney (Eds.).
213. Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 1976, 84:181.
214. Franks AL, Binkin NJ, Snider DE, et al. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep 1989, 104:151.
215. Snider DE, Caras GJ Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992, 145:494.
216. Steele MA, Des Prez RM The role of pyrazinamide in tuberculosis chemotherapy. Chest 1988, 94:845.
217. Hong Kong Chest Service/British Medical Research Council Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Am Rev Respir Dis 1991, 143:700.
218. Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000, 283(19):2537.
219. Chan ED, Iseman MD Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr Opin Infect Dis 2008, 21(6):587.
220. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003, 167:603.
221. Joint Tuberculosis Committee of the British Thoracic Society BTS guidelines - control and prevention of tuberculosis in the United Kingdom. Code of Practice 2000. Thorax 2000, 55:887.
222. World Health Organization Treatment of Tuberculosis: Guidelines for National Programmes. Report No. WHO/CDS/TB/2003.313 2003, World Health Organization, Geneva.
223. Enarson DA, Rieder HL, Arnadottir T, et al. Management of Tuberculosis: A Guide for Low Income Countries 2000, pmi Verl.-Gruppe, Frankfurt am Main, Germany. 5th ed.
224. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005, 172(9):1169.
225. China Tuberculosis Control Collaboration Results of directly observed short-course chemotherapy in 112,842 Chinese patients with smear-positive tuberculosis. Lancet 1996, 347:358.
226. Wilkinson D High-compliance tuberculosis treatment programme in a rural community. Lancet 1994, 343:647.
227. Frieden TR, Fujiwara PI, Washko RM, et al. Tuberculosis in New York City - turning the tide. N Engl J Med 1995, 333:229.
228. Cohn DL, Catlin BJ, Peterson KL, et al. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med 1990, 112:407.
229. Combs DL, O'Brien RJ, Geiter LJ USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 1990, 112:397.
230. Jindani A, Nunn AJ, Enarson DA Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: International multicentre randomised trial. Lancet 2004, 364:1244.
231. Okwera A, Whalen C, Byekwaso F, et al. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet 1994, 344:1323.
232. Chintu C, Luo C, Bhat G, et al. Cutaneous hypersensitivity reactions due to thiacetazone in the treatment of tuberculosis in Zambian children infected with HIV-I. Arch Dis Child 1993, 68:665.
233. Kelly P, Buve A, Foster SD, et al. Cutaneous reactions to thiacetazone in Zambia - implications for tuberculosis treatment strategies. Trans R Soc Trop Med Hyg 1994, 88:113.
234. Perriens JH, Colebunders RL, Karahunga C, et al. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with "standard" chemotherapy in Kinshasa, Zaire. Am Rev Respir Dis 1991, 144:750.
235. Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999, 353(9151):444.
236. Fennelly KP, Martyny JW, Fulton KE, et al. Cough-generated aerosols of Mycobacterium tuberculosis: a new method to study infectiousness. Am J Respir Crit Care Med 2004, 169(5):604.
237. Hernandez-Garduno E, Cook V, Kunimoto D, et al. Transmission of tuberculosis from smear negative patients: a molecular epidemiology study. Thorax 2004, 59(4):286.
238. Tostmann A, Kik SV, Kalisvaart NA, et al. Tuberculosis transmission by patients with smear-negative pulmonary tuberculosis in a large cohort in the Netherlands. Clin Infect Dis 2008, 47(9):1135.
239. British Thoracic Association A controlled trial of six months chemotherapy in pulmonary tuberculosis. First report: results during chemotherapy. Br J Dis Chest 1981, 75:141.
240. Hong Kong Chest Service/British Medical Research Council Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet 1981, 1:171.
241. Mitchison DA Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993, 147:1062.
242. Rieder HL Sputum smear conversion during directly observed treatment for tuberculosis. Tuberc Lung Dis 1996, 77:124.
243. Kiblawi SS, Jay SJ, Stonehill RB, et al. Fever response of patients on therapy for pulmonary tuberculosis. Am Rev Respir Dis 1981, 123:20.
244. Barnes PF, Chan LS, Wong SF The course of fever during treatment of pulmonary tuberculosis. Tubercle 1987, 68:255.
245. Ma Z, Lienhardt C, McIlleron H, et al. Global tuberculosis drug development pipeline: the need and the reality. The Lancet, Early Online Publication, May 19, 2010. doi:10.1016/S0140-6736(10)60359-60359.
246. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002, 360:528.
247. Tuberculosis Research Centre, Chennai Shortening short course chemotherapy: a randomized clinical trial for treatment of smear-positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian J Tuberc 2002, 49:27.
248. Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000, 405:962.
249. McGee B, Dietze R, Hadad DJ, et al. Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2009, 53(9):3981.
250. Diacn AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009, 360:2397.
251. Hamadeh MA, Glassroth J Tuberculosis and pregnancy. Chest 1992, 101:1114.
252. Ormerod P Tuberculosis in pregnancy and the puerperium. Thorax 2001, 56:494.
253. Shin S, Guerra D, Rich M, et al. Treatment of multidrug-resistant tuberculosis during pregnancy: a report of 7 cases. Clin Infect Dis 2003, 36:996.
254. American Academy of Pediatrics Committee on Drugs The transfer of drugs and other chemicals into human milk. Pediatrics 1994, 93:137.
255. Dutt AK, Moers D, Stead WW Short-course chemotherapy for extrapulmonary tuberculosis. Nine years' experience. Ann Intern Med 1986, 104:7.
256. Korenromp EL, Scano F, Williams BG, et al. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis 2003, 37(1):101.
257. Anonymous Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR Morb Mortal Wkly Rep 2002, 51:214.
258. el-Sadr WM, Perlman DC, Matts JP, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1998, 26:1148.
259. Nunn P, Brindle R, Carpenter L, et al. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality. Am Rev Respir Dis 1992, 146:849.
260. Alwood K, Keruly J, Moore-Rice K, et al. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients. AIDS 1994, 8:1103.
261. Breen RA, Miller RF, Gorsuch T, et al. Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy. J Infect Dis 2006, 193(10):1437.
262. Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998, 158:157.
263. Chien JW, Johnson JL Paradoxical reactions in HIV and pulmonary TB. Chest 1998, 114:933.
264. Meintjes G, Wilkinson KA, Rangaka MX, et al. Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2008, 178(10):1083.
265. Fitzgerald DW, Desvarieux M, Severe P, et al. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet 2000, 356:1470.
266. Churchyard GJ, Fielding K, Charalambous S, et al. Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy?. AIDS 2003, 17:2063.
267. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010, 362:697.
268. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008, 300(5):530.
269. Snider DE, Kelly GD, Cauthen GM, et al. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis 1985, 132:125.
270. Teixeira L, Perkins MD, Johnson JL, et al. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001, 5:321.
271. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003, 348:119.
272. Farmer P, Kim JY Community based approaches to the control of multidrug resistant tuberculosis: Introducing "DOTS-plus". BMJ 1998, 317:671.
273. Turett GS, Telzak EE, Torian LV, et al. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis 1995, 21:1238.
274. WHO Guidelines for Programmatic Management of Drug-Resistant Tuberculosis: 2006. Report No: WHO/HTM/TB/2006.361 2006, WHO, Geneva.
275. Swai OB, Aluoch JA, Githui WA, et al. Controlled clinical trial of a regimen of two durations for the treatment of isoniazid resistant pulmonary tuberculosis. Tubercle 1988, 69:5.
276. Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. The results up to 30 months. Am Rev Respir Dis 1977, 115:727.
277. Pomerantz M, Madsen L, Goble M, et al. Surgical management of resistant mycobacterial tuberculosis and other mycobacterial pulmonary infections. Ann Thorac Surg 1995, 52:1108.
278. Pomerantz BJ, Cleveland JC, Olson HK, et al. Pulmonary resection for multi-drug resistant tuberculosis. J Thorac Cardiovasc Surg 2001, 121:448.
279. Crofton J, Chaulet P, Maher D Guidelines for the Management of Drug-Resistant Tuberculosis. Report No. WHO/TB/96.210 (Rev. 1) 1997, World Health Organization, Geneva.
280. Iseman MD Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993, 329:784.
281. Bradford WZ, Daley CL Multiple drug-resistant tuberculosis. Infect Dis Clin North Am 1998, 12:157.
282. Partners in Health/Harvard Medical School/Bill & Melinda Gates Foundation A DOTS-Plus Handbook. Guide to the Community-Based Treatment of MDR TB 2002, Partners in Health, Boston.
283. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009, 360(23):2397.
284. Hugonnet JE, Tremblay LW, Boshoff HI, et al. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009, 323(5918):1215.
285. Comstock GW Field trials of tuberculosis vaccines: how could we have done them better?. Control Clin Trials 1994, 15:247.
286. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994, 271:698.
287. Mostowy S, Tsolaki AG, Small PM, et al. The in vitro evolution of BCG vaccines. Vaccine 2003, 21:4270.
288. Rodrigues LC, Diwan VK, Wheeler JG Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993, 22:1154.
289. ten Dam HG BCG vaccination and HIV infection. Bull IUATLD 1990, 65:38.
290. WHO Global Programme on AIDS/Tuberculosis Programme. AIDS and tuberculosis. Wkly Epidemiol Rec 1989, 64:125.
291. McMurray DN Recent progress in the development and testing of vaccines against human tuberculosis. Int J Parasitol 2003, 33:547.
292. Ferebee SH Controlled chemoprophylaxis trials in tuberculosis. A general review. Adv Tuberc Res 1970, 17:28.
293. Comstock GW, Baum C, Snider DE Isoniazid prophylaxis among Alaskan Eskimos: a final report of the Bethel isoniazid studies. Am Rev Respir Dis 1979, 119:827.
294. Comstock GW, Ferebee SH How much isoniazid is needed for prophylaxis?. Am Rev Respir Dis 1970, 101:780.
295. International Union Against Tuberculosis Committee on Prophylaxis Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull WHO 1982, 60:555.
296. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997, 337:801.
297. Joint Tuberculosis Committee of the British Thoracic Society Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998, 53:536.
298. Hong Kong Chest Service/Tuberculosis Research Center MBMRC A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992, 145:36.
299. Riska N Hepatitis cases in isoniazid treated groups and in a control group. Bull Int Union Tuberc 1976, 51:203.
300. Bucher HC, Griffith LE, Guyatt GH, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999, 13:501.
301. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003. MMWR Morb Mortal Wkly Rep 2003, 52:735.
302. Fitzgerald DW, Severe P, Joseph P, et al. No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial. J Acquir Immune Defic Syndr 2001, 28:305.
303. Gordin FM, Matts JP, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med 1997, 337:315.
304. Fitzgerald DW, Morse MM, Pape JW, et al. Active tuberculosis in individuals infected with human immunodeficiency virus after isoniazid prophylaxis. Clin Infect Dis 2000, 31:1495.
305. Johnson JL, Okwera A, Hom DL, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001, 15:2137.
306. Quigley MA, Mwinga A, Hosp M, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001, 15:215.
307. Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009, 23(5):631.
308. Wolinsky E Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 1979, 119:107.
309. Pitchenik AE, Fertel D Medical management of AIDS patients. Tuberculosis and nontuberculous mycobacterial disease. Med Clin North Am 1992, 76:121.
310. Wallace RJ Nontuberculous mycobacterial infections in the HIV-negative host. Tuberculosis 1996, 699. Little, Brown, Boston. W.N. Rom, S.M. Garay (Eds.).
311. Wolinsky E Mycobacterial lymphadenitis in children: a prospective study of 105 nontuberculous cases with long-term follow-up. Clin Infect Dis 1995, 20:954.
312. van der Werf TS, Stinear T, Stienstra Y, et al. Mycolactones and Mycobacterium ulcerans disease. Lancet 2003, 362:1062.
313. American Thoracic Society Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997, 156:S1.
314. Rosenzweig DY Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases. Chest 1979, 75:115.
315. Kennedy TP, Weber DJ Nontuberculous mycobacteria. An underappreciated cause of geriatric lung disease. Am J Respir Crit Care Med 1994, 149:1654.
316. Prince DS, Peterson DD, Steiner RM, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989, 321:863.
317. Reich JM, Johnson RE Mycobacterium avium complex pulmonary disease. Incidence, presentation, and response to therapy in a community setting. Am Rev Respir Dis 1991, 143:1381.
318. Iseman MD Medical management of pulmonary disease caused by Mycobacterium avium complex. Clin Chest Med 2002, 23:633.
319. Gilks CF, Brindle RJ, Mwachari C, et al. Disseminated Mycobacterium avium infection among HIV-infected patients in Kenya. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8:195.
320. Ssali FN, Kamya MR, Wabwire-Mangen F, et al. A prospective study of community-acquired bloodstream infections among febrile adults admitted to Mulago Hospital in Kampala, Uganda. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:484.
321. Eaton T, Falkinham JO, Aisu TO, et al. Isolation and characteristics of Mycobacterium avium complex from water and soil samples in Uganda. Tuberc Lung Dis 1995, 76:570.
322. Horsburgh CR Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991, 324:1332.
323. Horsburgh CR, Havlik JA, Ellis DA, et al. Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. Am Rev Respir Dis 1991, 144:557.
324. Jacobson MA, Hopewell PC, Yajko DM, et al. Natural history of disseminated Mycobacterium avium complex infection in AIDS. J Infect Dis 1991, 164:994.
325. Parenti DM, Williams PL, Hafner R, et al. A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individuals. AIDS 1998, 12:2439. AIDS Clinical Trials Group Protocol 135 Study Team.
326. Gordin FM, Sullam PM, Shafran SD, et al. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin Infect Dis 1999, 28:1080.
327. Centers for Disease Control and Prevention Guidelines for Preventing Opportunistic Infections Among HIV-Infected Persons - 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep 2002, 51:1.
328. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med 1996, 335:392.
329. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996, 335:384.
330. Kaplan JE, Benson C, Homes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009, 58(RR-4):1.
331. Wolinsky E Mycobacterial diseases other than tuberculosis. Clin Infect Dis 1992, 15:1.
332. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society. Thorax 2000, 55:210.
333. Wolinsky E Mycobacterial lymphadenitis in children: a prospective study of 105 nontuberculous cases with long-term follow-up. Clin Infect Dis 1995, 20:954.
334. Gonzalez OY, Teeter LD, Thanh BT, et al. Extrathoracic tuberculosis lymphadenitis in adult HIV seronegative patients: a population-based analysis in Houston, Texas, USA. Int J Tuberc Lung Dis 2003, 7:987.
335. Lau SK, Kwan S, Lee J, et al. Source of tubercle bacilli in cervical lymph nodes: a prospective study. J Laryngol Otol 1991, 105:558.
336. Appling D, Miller RH Mycobacterium cervical lymphadenopathy: 1981 update. Laryngoscope 1981, 91:1259.
337. Huhti E, Brander E, Paloheimo S, et al. Tuberculosis of the cervical lymph nodes: a clinical, pathological and bacteriological study. Tubercle 1975, 56:27.
338. Lau SK, Wei WI, Hsu C, et al. Efficacy of fine needle aspiration cytology in the diagnosis of tuberculous cervical lymphadenopathy. J Laryngol Otol 1990, 104:24.
339. Bem C, Patil PS, Elliott AM, et al. The value of wide-needle aspiration in the diagnosis of tuberculous lymphadenitis in Africa. AIDS 1993, 7:1221.
340. British Thoracic Society Research Committee Short course chemotherapy for lymph node tuberculosis: final report at 5 years. Br J Dis Chest 1988, 82:282.
341. Iwnetu R, van den Hombergh J, Woldeamanuel Y, et al. Is tuberculous lymphadenitis over-diagnosed in Ethiopia? Comparative performance of diagnostic tests for mycobacterial lymphadenitis in a high-burden country. Scand J Infect Dis 2009, 41(6-7):462.
342. Cho OH, Park KH, Kim T, et al. Paradoxical responses in non-HIV-infected patients with peripheral lymph node tuberculosis. J Infect 2009, 59(1):56.
343. Gorse GJ, Pais MJ, Kusske JA, et al. Tuberculous spondylitis. A report of six cases and a review of the literature. Medicine (Baltimore) 1983, 62:178.
344. Kroot EJ, Hazes JM, Colin EM, Dolhain RJ Poncet's disease: reactive arthritis accompanying tuberculosis. Two case reports and a review of the literature. Rheumatology (Oxford) 2007, 46(3):484.
345. Berney S, Goldstein M, Bishko F Clinical and diagnostic features of tuberculous arthritis. Am J Med 1972, 53:36.
346. Hodgman JR, Skinsnes DH, Leong CY The pathogenesis of Pott's paraplegia. J Bone Joint Surg Am 1967, 49:1167.
347. Wise GJ, Marella VK Genitourinary manifestations of tuberculosis. Urol Clin North Am 2003, 30:111.
348. Simon HB, Weinstein AJ, Pasternak MS, et al. Genitourinary tuberculosis. Clinical features in a general hospital population. Am J Med 1977, 63:410.
349. Christensen WI Genitourinary tuberculosis: review of 102 cases. Medicine (Baltimore) 1974, 53:377.
350. Lattimer JK Renal tuberculosis. N Engl J Med 1965, 273:208.
351. Zarrabi AD, Heyns CF Clinical features of confirmed versus suspected urogenital tuberculosis in region with extremely high prevalence of pulmonary tuberculosis. Urology 2009, 74(1):41.
352. Sutherland AM Gynaecological tuberculosis: analysis of a personal series of 710 cases. Aust N Z J Obstet Gynaecol 1985, 25:203.
353. Gorse GJ, Belshe RB Male genital tuberculosis: a review of the literature with instructive case reports. Rev Infect Dis 1985, 7:511.
354. Hageman JH, D'Esopo ND, Glenn WW Tuberculosis of the pericardium. A long-term analysis of forty-four proved cases. N Engl J Med 1964, 270:327.
355. Rooney JJ, Crocco JA, Lyons HA Tuberculous pericarditis. Ann Intern Med 1970, 72:73.
356. Fowler NO, Manitsas GT Infectious pericarditis. Prog Cardiovasc Dis 1973, 16:323.
357. Strang JI, Kakaza HH, Gibson DG, et al. Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet 1988, 2:759.
358. Reuter H, Burgess L, van Vuuren W, Doubel A Diagnosing tuberculous pericarditis. Q J Med 2006, 99(12):827.
359. Strang JIG, Nunn AJ, Johnson DA, et al. Management of tuberculous constrictive pericarditis and tuberculous pericardial effusion in Transkei: results at 10 years follow-up. Q J Med 2004, 97:525.
360. Strang JI, Kakaza HH, Gibson DG, et al. Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet 1987, 2:1418.
361. Hakim JG, Ternouth I, Mushangi E, et al. Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients. Heart 2000, 84:183.
362. Bastani B, Shariatzadeh MR, Dehdashti F Tuberculous peritonitis - report of 30 cases and review of the literature. Q J Med 1985, 56:549.
363. Burack WR, Hollister RM Tuberculous peritonitis. A study of forty-seven proved cases encountered by a general medical unit in twenty-five years. Am J Med 1960, 28:510.
364. Karney WW, O'Donoghue JM, Ostrow JH, et al. The spectrum of tuberculous peritonitis. Chest 1977, 72:310.
365. Singh MM, Bhargava AN, Jain KP Tuberculous peritonitis. An evaluation of pathogenetic mechanisms, diagnostic procedures and therapeutic measures. N Engl J Med 1969, 281:1091.
366. Jorge AD Peritoneal tuberculosis. Endoscopy 1984, 16:10.
367. Kakakhel KU, Fritsch P Cutaneous tuberculosis. Int J Dermatol 1989, 28:355.
368. Wortman PD Pulmonary and cutaneous tuberculosis. J Am Acad Dermatol 1992, 27:459.
369. Marcoval J, Servitje O, Moreno A, et al. Lupus vulgaris. Clinical, histopathologic, and bacteriologic study of 10 cases. J Am Acad Dermatol 1992, 26:404.
370. Slavin RE, Walsh TJ, Pollack AD Late generalized tuberculosis: a clinical pathologic analysis and comparison of 100 cases in the preantibiotic and antibiotic eras. Medicine (Baltimore) 1980, 59:352.
371. Newton P, Sharp J, Barnes KL Bone and joint tuberculosis in greater Manchester. Ann Rheum Dis 1982, 41:1969-1979.
372. Davies PD, Humphries MJ, Byfield SP, et al. Bone and joint tuberculosis. A survey of notifications in England and Wales. J Bone Joint Surg Br 1984, 66:326.
373. Hold J The value of histological and bacteriological examination in the tuberculosis of bones and joints. Acta Orthop Scand 1964, 35:91.
374. Medical Research Council Working Party on Tuberculosis of the Spine First report: a controlled trial of ambulant outpatient treatment and in-patient rest in bed in the management of tuberculosis of the spine in young Korean patients on standard chemotherapy. J Bone Joint Surg Br 1973, 55:678.
375. Medical Research Council Working Party on Tuberculosis of the Spine Fifth report: a five-year assessment of controlled trials of in-patient and out-patient treatment and of plaster-of-Paris jackets for tuberculosis of the spine in children on standard chemotherapy. Studies in Masan and Pusan, Korea. J Bone Joint Surg Br 1976, 58B:399.
376. Medical Research Council Working Party on Tuberculosis of the Spine Sixth report: five-year assessments of controlled trials of ambulatory treatment, debridement and anterior spinal fusion in the management of tuberculosis of the spine. Studies in Bulawayo (Rhodesia) and in Hong Kong. J Bone Joint Surg Br 1978, 60B:163.
377. Medical Research Council Working Party on Tuberculosis of the Spine Eighth report: a 10-year assessment of a controlled trial comparing debridement and anterior spinal fusion in the management of tuberculosis of the spine in patients on standard chemotherapy in Hong Kong. J Bone Joint Surg Br 1982, 64:393.